Literature DB >> 25749868

Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.

Eric J Niesor1, Gregory G Schwartz, Anne Perez, Andrea Stauffer, Alexandre Durrwell, Gabriela Bucklar-Suchankova, Renée Benghozi, Markus Abt, David Kallend.   

Abstract

PURPOSE: Cholesterol efflux from macrophages to HDL, measured in vitro, is augmented by treatment with agents which raise HDL cholesterol. In vitro, cholesterol depletion by statins is known to trigger a positive feedback on the cholesterol synthetic pathway via sterol regulatory element-binding protein (SREBP) transcription and changes in expression of SREBP regulated genes including microRNA33 (miR33) which is co-transcribed with SREBP and down-regulates ABCA1 and ABCG1 expression.
METHODS: We investigated whether miR33 up-regulation, associated with SREBP increased transcription by statins, reduces macrophage ATP-binding cassette (ABC) transporter expression, thereby decreasing HDL-mediated cholesterol efflux at the tissue level.
RESULTS: In human macrophage THP-1 cells cholesterol-loaded with acetylated LDL, incubation with 1 μM atorvastatin increased miR33 by 33 % (P < 0.05), and decreased ABCA1 messenger RNA (mRNA) and ABCG1 mRNA by 47 % (P < 0.05) and 27 % (NS), respectively. In J774A.1 mouse macrophage, labelled with 3H-cholesterol, ABCA1 mRNA and ABCA1-mediated cholesterol efflux were decreased by 1 μM statin: simvastatin > pitavastatin > atorvastatin > rosuvastatin > pravastatin. HDL incubated with rhCETP and dalcetrapib increased ABCA1-mediated cholesterol efflux. However, incremental simvastatin concentrations decreased cholesterol efflux to HDL treated with rhCETP and dalcetrapib. When HDL was incubated with rhCETP, addition of dalcetrapib augmented ABCA1-mediated cholesterol efflux from J774A.1 macrophages. However, simvastatin ≥1 μM virtually eliminated any HDL-ABCA1-mediated cholesterol efflux and any augmentation of that process by dalcetrapib.
CONCLUSIONS: In vitro, statins increase miR33 expression, and decrease ABCA1 expression and cholesterol efflux from peripheral tissues; this may counteract the potential benefit of agents that raise HDL and apolipoprotein A-I in statin-treated patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25749868     DOI: 10.1007/s10557-015-6570-0

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  19 in total

1.  Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.

Authors:  Cristiano P Vieira; Seth D Fortmann; Masroor Hossain; Ana Leda Longhini; Sandra S Hammer; Bright Asare-Bediako; David K Crossman; Micheli S Sielski; Yvonne Adu-Agyeiwaah; Mariana Dupont; Jason L Floyd; Sergio Li Calzi; Todd Lydic; Robert S Welner; Gary J Blanchard; Julia V Busik; Maria B Grant
Journal:  JCI Insight       Date:  2020-07-09

2.  Genetic contribution to lipid target achievement with statin therapy: a prospective study.

Authors:  Cristina Ruiz-Iruela; Beatriz Candás-Estébanez; Xavier Pintó-Sala; Neus Baena-Díez; Assumpta Caixàs-Pedragós; Roser Güell-Miró; Rosa Navarro-Badal; Pilar Calmarza; Jose Luis Puzo-Foncilla; Pedro Alía-Ramos; Ariadna Padró-Miquel
Journal:  Pharmacogenomics J       Date:  2019-12-06       Impact factor: 3.550

Review 3.  Disordered haematopoiesis and athero-thrombosis.

Authors:  Andrew J Murphy; Alan R Tall
Journal:  Eur Heart J       Date:  2016-02-10       Impact factor: 29.983

4.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

Review 5.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

Review 6.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

7.  Atorvastatin Upregulates the Expression of miR-126 in Apolipoprotein E-knockout Mice with Carotid Atherosclerotic Plaque.

Authors:  Xudong Pan; Rongyao Hou; Aijun Ma; Ting Wang; Mei Wu; Xiaoyan Zhu; Shaonan Yang; Xing Xiao
Journal:  Cell Mol Neurobiol       Date:  2016-02-17       Impact factor: 5.046

8.  Pitavastatin Differentially Modulates MicroRNA-Associated Cholesterol Transport Proteins in Macrophages.

Authors:  Haijun Zhang; Brian D Lamon; George Moran; Tao Sun; Antonio M Gotto; David P Hajjar
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

Review 9.  The Regulation of Reverse Cholesterol Transport and Cellular Cholesterol Homeostasis by MicroRNAs.

Authors:  Diana M DiMarco; Maria Luz Fernandez
Journal:  Biology (Basel)       Date:  2015-07-28

Review 10.  Structural Insights into High Density Lipoprotein: Old Models and New Facts.

Authors:  Valentin Gogonea
Journal:  Front Pharmacol       Date:  2016-01-12       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.